Trial *
Publication Podder C, IMC J Med Sci (2020) (published paper)
Dates: 2020-05-01 to 2020-07-31
Funding: No specific funding (Self-financed)
Conflict of interest: No

Methods
RCT
Blinding: Unblinded
Location : Single center / Bangladesh
Follow-up duration (days): 10
Inclusion criteria
  • Consecutive RT-PCR positive eligible mild to moderate COVID-19 cases of more than 18 years of age, of both sexes
Exclusion criteria
  • Known pre-existing hypersensitivity to Ivermectin, pregnant and lactating mothers, and patients taking other antimicrobials or hydroxychloroquine
Interventions
Treatment
Ivermectin
Control
Standard care


Participants
Randomized
NR

Analyzed
62 participants Ivermectin=32
Standard care=30
Characteristics of participants
N= 62
Mean age : NR
44 males
Severity : Mild: n= 62/ Asymptomatic: n=0
Number of vaccinated participants: NR
Primary outcome
In the register
NR
In the report
Time needed for resolution of fever, cough, shortness of breath and finally, full recovery from all symptoms and the negative result of repeat RT-PCR on day 10.
Documents
available

Protocol

NR

Statistical plan

NR

Data-sharing willing stated in the publication:
Risk of bias
Overall
The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review
High
General comment Only the published article was used in data extraction and risk of bias assessment as no study registry, protocol or analysis plan was available. No a priori sample size determination was reported. The randomized proportion of participants per group was not reported. Patients were allocated to treatment groups using a quasi-randomisation method, based on odd and even registration numbers in a consecutive fashion. After allocation, a sizeable proportion of patients was not included in the analysis due to the prior duration of symptoms and it is unclear whether this was a post hoc decision.